Discounted Cash Flow
Bio-rad Laboratories, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $2.1b | $28.1m | $75.0m | 1.4% | $0.96 |
| 2017 | $2.2b (4.4%) | $122.2m (334.7%) | $-7.4m (-109.9%) | 5.7% (316.2%) | $4.12 (329.2%) |
| 2018 | $2.3b (6.0%) | $365.6m (199.1%) | $155.7m (2190.4%) | 16.0% (182.2%) | $12.25 (197.3%) |
| 2019 | $2.3b (1.0%) | $1.8b (381.0%) | $359.4m (130.9%) | 76.1% (376.4%) | $58.93 (381.1%) |
| 2020 | $2.5b (10.1%) | $3.8b (116.4%) | $476.4m (32.6%) | 149.5% (96.5%) | $127.86 (117.0%) |
| 2021 | $2.9b (14.8%) | $4.2b (11.6%) | $535.7m (12.4%) | 145.3% (-2.8%) | $142.33 (11.3%) |
| 2022 | $2.8b (-4.1%) | $-3.6b (-185.4%) | $81.7m (-84.8%) | -129.5% (-189.1%) | $-121.79 (-185.6%) |
| 2023 | $2.7b (-4.7%) | $-637.3m (82.4%) | $218.3m (167.3%) | -23.9% (81.6%) | $-21.82 (82.1%) |
| 2024 | $2.6b (-3.9%) | $-1.8b (-189.4%) | $289.6m (32.7%) | -71.9% (-201.2%) | $-65.36 (-199.5%) |
| 2025 | $2.6b (0.7%) | $759.9m (141.2%) | $374.6m (29.4%) | 29.4% (140.9%) | $27.87 (142.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.